Journal of Antimicrobial Chemotherapy, Vol 41, 481-484, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
FJ Schmitz, B Hofmann, B Hansen, S Scheuring, M Luckefahr, M Klootwijk, J Verhoef, A Fluit, HP Heinz, K Kohrer and ME Jones
The in-vitro activities of five fluoroquinolones were tested against 70
ciprofloxacin-resistant and 46 ciprofloxacin-susceptible unrelated isolates
of Staphylococcus aureus. All 116 S. aureus isolates were studied for the
presence of mutations in the grl and gyr loci. The order of efficacy of the
fluoroquinolones tested, from least to most active, was: ciprofloxacin,
ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039), in
response to all characterized mutations in grlA, grlB, gyrA and gyrB.
Moxifloxacin was active against most S. aureus isolates tested (MIC90 = 1
mg/L for ciprofloxacin-resistant isolates) and was less influenced by known
mutations.
ORIGINAL ARTICLES
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus
Institute for Medical Microbiology and Virology, Heinrich-Heine University, Dusseldorf, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. T. Black, T. Stachyra, D. Platel, A.-M. Girard, M. Claudon, J.-M. Bruneau, and C. Miossec Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3339 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. H. Tam, A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano The Relationship between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: a New Paradigm for Optimizing Pharmacodynamics To Counterselect Resistance Antimicrob. Agents Chemother., February 1, 2007; 51(2): 744 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Malincarne, M. Ghebregzabher, M. V. Moretti, A. M. Egidi, B. Canovari, G. Tavolieri, D. Francisci, G. Cerulli, and F. Baldelli Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty J. Antimicrob. Chemother., May 1, 2006; 57(5): 950 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagaoka, T. Horii, T. Satoh, T. Ito, A. Monji, A. Takeshita, and M. Maekawa Use of a Three-Dimensional Microarray System for Detection of Levofloxacin Resistance and the mecA Gene in Staphylococcus aureus J. Clin. Microbiol., October 1, 2005; 43(10): 5187 - 5194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2642 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Trong, A.-L. Prunier, and R. Leclercq Hypermutable and Fluoroquinolone-Resistant Clinical Isolates of Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2005; 49(5): 2098 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Christiansen, J. M. Bell, J. D. Turnidge, and R. N. Jones Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lapierre, A. Huletsky, V. Fortin, F. J. Picard, P. H. Roy, M. Ouellette, and M. G. Bergeron Real-Time PCR Assay for Detection of Fluoroquinolone Resistance Associated with grlA Mutations in Staphylococcus aureus J. Clin. Microbiol., July 1, 2003; 41(7): 3246 - 3251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Kaatz, V. V. Moudgal, and S. M. Seo Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2002; 50(6): 833 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hannachi-M'Zali, J. E. Ambler, C. F. Taylor, and P. M. Hawkey Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC) J. Antimicrob. Chemother., November 1, 2002; 50(5): 649 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, M. Boos, S. Mayer, H. Jagusch, and A. C. Fluit Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., February 1, 2002; 49(2): 283 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Linde, M. Schmidt, E. Fuchs, U. Reischl, H.-H. Niller, and N. Lehn In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1553 - 1557. [Abstract] [Full Text]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, A. Beeck, M. Perdikouli, and C. von Eiff Development of chromosomally encoded resistance mutations in small-colony variants of Staphylococcus aureus J. Antimicrob. Chemother., January 1, 2001; 47(1): 113 - 115. [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, D. Hafner, A. Beeck, M. Perdikouli, M. Boos, S. Scheuring, J. Verhoef, K. Köhrer, and C. Von Eiff Development of Resistance to Ciprofloxacin, Rifampin, and Mupirocin in Methicillin-Susceptible and -Resistant Staphylococcus aureus Isolates Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3229 - 3231. [Abstract] [Full Text]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, D. Milatovic, J. Verhoef, H.-P. Heinz, and S. Brisse In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., July 1, 2000; 46(1): 109 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bisognano, P. Vaudaux, P. Rohner, D. P. Lew, and D. C. Hooper Induction of Fibronectin-Binding Proteins and Increased Adhesion of Quinolone-Resistant Staphylococcus aureus by Subinhibitory Levels of Ciprofloxacin Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1428 - 1437. [Abstract] [Full Text]
|
|
|
|
|
|
H. F. Chambers, Q. Xiang, Liu, L. L. Chow, and C. Hackbarth Efficacy of Levofloxacin for Experimental Aortic-Valve Endocarditis in Rabbits Infected with Viridans Group Streptococcus or Staphylococcus aureus Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2742 - 2746. [Abstract] [Full Text]
|
|
|
|
|
|
D. T. Dubin, J. E. Fitzgibbon, M. D. Nahvi, and J. F. John Topoisomerase Sequences of Coagulase-Negative Staphylococcal Isolates Resistant to Ciprofloxacin or Trovafloxacin Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1631 - 1637. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Muñoz Bellido, M. A. Alonso Manzanares, G. Yagüe Guirao, M. N. Gutiérrez Zufiaurre, M. C. M. Toldos, M. Segovia Hernández, and J. A. García-Rodríguez In Vitro Activities of 13 Fluoroquinolones against Staphylococcus aureus Isolates with Characterized Mutations in gyrA, gyrB, grlA, and norA and against Wild-Type Isolates Antimicrob. Agents Chemother., April 1, 1999; 43(4): 966 - 968. [Abstract] [Full Text]
|
|